Abstract:We aim to summarize selected late-breaking science on hypertension management strategies and disease presented at the 2023 American Heart Association (AHA) conference. The trials discussed below encompass stricter goals of blood pressure management and were expanded into different population groups from different countries with varied socioeconomic backgrounds and settings, collectively advancing our understanding of hypertension treatment and its impact on public health. We summarized the china rural health care project (CRHCP), a four-year study involving over 34,000 participants in rural China, emphasizing the potential of stricter blood pressure goals in lowering the incidence of all-cause dementia and cognitive impairment. Next, we explore the US-based CARDIA-SSBP study, which highlights the impact of dietary sodium on systolic blood pressure in middle-aged individuals. Through a randomized-order cross-over design, the study provides compelling evidence supporting the effectiveness of sodium reduction as a non-pharmacological approach to blood pressure control. The UK-based POP-HT trial offers critical insights into postpartum women with a history of hypertensive pregnancy. The trial emphasizes the benefits of self-monitoring and physician-optimized antihypertensive titration, showcasing significant blood pressure reductions in the intervention group. Furthermore, the KARDIA-1 study introduces us to Zilebesiran, an innovative RNA interference drug. This phase 2 study highlights its potential for achieving sustained blood pressure reductions and its favorable safety profile, marking a significant step forward in hypertension treatment. Lastly, we expand the practical application of the previously conducted landmark SPRINT trial, which showed cardiovascular benefit with intensive SBP control to less than 120 mm Hg in high-risk non-diabetic patients with hypertension compared with routine BP control to <140 mm Hg. The ESPRIT trial and the IMPACTS trial build upon the SPRINT trial, demonstrating the effects of intensive blood pressure lowering in Asian hypertensive patients and in 36 health care clinics in medically underserved states in the US: Louisiana and Mississippi. The IMPACTS trial and the "Hypertension Treatment in Nigeria Program" demonstrate the effectiveness of implementing comprehensive blood pressure control strategies in real-world settings. These studies highlight the feasibility and scalability of such interventions, especially in low-resource environments, and their potential to significantly improve public health outcomes.

Milestone Papers in Signal Transduction Mechanisms of Hypertension and Its Complications

Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions

Emerging topics on basic research in hypertension: interorgan communication and the need for interresearcher collaboration

Immune mechanisms in the pathophysiology of hypertension

Key hypertension breakthroughs and emerging trends from the AHA's scientific sessions

Molecular Mechanisms Underlying Vascular Remodeling in Hypertension

Immune Mechanisms in Hypertension

Innovations in blood pressure measurement and reporting technology: International Society of Hypertension position paper endorsed by the World Hypertension League, European Society of Hypertension, Asian Pacific Society of Hypertension, and Latin American Society of Hypertension

Vascular structural and functional changes: their association with causality in hypertension: models, remodeling and relevance

Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review

Immune mechanisms in arterial hypertension. Recent advances

Hypertension research 2024 update and perspectives: basic research

Update on Immune Mechanisms in Hypertension

The Sympathetic Nervous System in Hypertension: Roadmap Update of a Long Journey

The Causal Relationship between Endothelin-1 and Hypertension: Focusing on Endothelial Dysfunction, Arterial Stiffness, Vascular Remodeling, and Blood Pressure Regulation

Immunological insights into hypertension: unraveling triggers and potential therapeutic avenues

Recent advancements in targeting the immune system to treat hypertension

The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension

Pathophysiology of Angiotensin II-Mediated Hypertension, Cardiac Hypertrophy, and Failure: A Perspective from Macrophages

Overview of the Evolution of Hypertension: From Ancient Chinese Emperors to Today

Thrombosis in Hypertension: Pathophysiology, Biomarkers, and the Effect of Antihypertensive Treatment